Mitochondrial dysfunction

Putilina M.V.

doi:https://doi.org/10.17116/jnevro202212209148

Putilina M.V.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-8655-8501

Mitochondrial dysfunction

Authors:

Putilina M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9): 48‑53

DOI: 10.17116/jnevro202212209148

Read: 23397 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Putilina MV. Mitochondrial dysfunction. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9):48‑53. (In Russ.)
https://doi.org/10.17116/jnevro202212209148

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12

Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14

Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138

Oxidative stress, ferroptosis, somatic mutations, antioxidant therapy, and endometriosis: a new perspective on the issue. Russian Journal of Human Reproduction. 2024;(6):32-44

Neuroprotective therapy for age-related macular degeneration. Russian Annals of Ophthalmology. 2024;(6):152-158

Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90

Morphological markers of mitochondrial dysfunction of the basal plate cytotrophoblast of the placenta in preeclampsia of varying severity. Russian Journal of Archive of Pathology. 2025;(2):24-29

Free radicals in reproductive processes. Russian Journal of Human Reproduction. 2025;(5):51-57

Abstract:

Hypoergos-energy deficiency, i.e., a mismatch between the body’s (tissue, organ, cell) need for energy and the limited amount of macroergs (ATP) that can currently be used to maintain the structural integrity and functional activity of a tissue or organ. The main role in the development of hypoergoses is played by damage to mitochondria, therefore, in recent years, this term has been replaced by mitochondrial dysfunction. Over the past 50 years, drugs have been actively studied and developed that have the ability to influence mitochondrial disorders, both primary and secondary mitochondrial diseases. In this context, Cytochrome C, an original antioxidant/antihypoxant with a dual mechanism of action, deserves attention

Keywords:

mitochondrial dysfunction

mitochondrial diseases

Cytochrome C

ATP

energy deficiency

antioxidants

antihypoxants

Authors:

Putilina M.V.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-8655-8501

Received:

06.07.2022

Accepted:

14.07.2022

Close metadata

References:

Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. https://doi.org/10.1038/s41591-021-01283-z
Putilina MV. Asthenic disorders in general medical practice. Algorithms of diagnostics and therapy. Nervous diseases. 2013;4:26-33. (In Russ.).
Kjeldsberg M, Tschudi-Madsen H, Mdala I, et al. Patients in general practice share a common pattern of symptoms that is partly independent of the diagnosis. Scand J Prim Health Care. 2021;39(2):184-193. https://doi.org/10.1080/02813432.2021.1913886
Efuni SN, Shpektor VA. Hypoxic conditions and their classification. Anesteziol Reanimatol. 1986;2:3-12. (In Russ.).
Legesse M, Abebe Z, Woldie H. Chronic energy deficiency and associated factors among older population in Ethiopia: A community-based study. PLoS ONE. 2019;14(4):e0214861. https://doi.org/10.1371/journal.pone.0214861
Zadnipryany IV, Tretyakova OS, Sataeva TP. Features of the devel- opment of mitochondrial dysfunction in hypoxic conditions. Int Sci Rev. 2016;12(2):23-29. (In Russ.).
Ilyukhina VA. Perinatal energy deficiency in a decrease in the level of health with disorders of neuropsychic and speech development. SPb. 2015;176. (In Russ.).
Marzetti E, Calvani R, Cesari M, et al. Mitochondrial dysfunction and sarcopenia of aging. Int J Biochem Cell Biol. 2013;45(10):2288-2301. https://doi.org/10.1016/j.biocel.2013.06.024
Chinnery PF. Primary Mitochondrial Disorders Overview. 2000 Jun 8 [Updated 2021 Jul 29]. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle. 1993-2022. https://www.ncbi.nlm.nih.gov/books/NBK1224
Davis RL, Liang C, Sue CM. Davis RL, et al. Mitochondrial diseases. Handb Clin Neurol. 2018;147:125-141. https://doi.org/10.1016/B978-0-444-63233-3.00010-5
Khan NA, Govindaraj P, Meena AK, Thangaraj K. Mitochondrial disorders: challenges in diagnosis & treatment. Indian J Med Res. 2015;141(1):13-26. https://doi.org/10.4103/0971-5916.154489
Putilina MV. Role of endothelial dysfunction in cerebrovascular diseases. Doctor. 2012;7:24-28. (In Russ.).
McEwen B, Nasca C, Gray J. Stress Effects on Neuronal Structure: Hippocampus, Amygdala, and Prefrontal Cortex. Neuropsychopharmacol. 2016;41:3-23. https://doi.org/10.1038/npp.2015.171
Putilina MV. Peculiarities of asthenic disorders therapy. Consilicum Medicum. 2010;1:30-35. (In Russ.).
Sapra A, Bhandari P. Chronic Fatigue Syndrome. [Updated 2021 Feb 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK557676/
Batysheva TT, Kondakova OB, Kvasova OV. Hereditary diseases in the practice of a pediatric neurologist. Guidelines. M., 2015. (In Russ.).
Putilina MV. Combined neuroprotective therapy in cerebrovascular diseases cerebrovascular diseases. Physician. 2012;4:69-73. (In Russ.).
Goroshko OA, Kukes VG, Prokofiev AB, et al. Clinical and pharmacological aspects of the use of antioxidant drugs. Int J Appl Basic Res. 2016;4-5:905-912. (In Russ.).
Vashchenko VI, Hanson KP, Shabanov PD. Cytochrome C as a drug: past, present, future. Rev Pharmacol Lek Ter. 2005;4(1):27-37. (In Russ.).
Instructions for the medical use of the drug Cytochrome C. LSR-008117/08-201218. (In Russ.).
Chertkova RV, Brazhe NA, Bryantseva TV, et al. New insight into the mechanism of mitochondrial cytochrome c function. PLoS One. 2017;12(5):e0178280. https://doi.org/10.1371/journal.pone.0178280
Ivkin DYu. Pathogenetic therapy of hypoxia of organs and tissues at the cellular level. Attending Physician. 2017;7:11-17. (In Russ.).
Cheltsov VV, Martynov AI, Gushchina YuSh, et al. Metabolic therapy in chronic heart failure. Therapy. 2016;4(8):54-60. (In Russ.).
Zinchenko VA. Therapy of hypoxic disorders in disorders of cerebral circulation and the use of cytochrome C in their correction. In: Cytochrome C and its clinical application. L.: LSRIH&TB; 1990;39-41. (In Russ.).
Report on the research work “Study of the specific pharmacological activity of the drug Cytochrome C, lyophilisate for solution for intravenous and intramuscular injection, 10 mg, in a model of ischemic stroke in rats. Leningrad region, 2019;291. (In Russ).
Sukalo AV, Tkachenko AK, Khrustaleva EK, et al. Transient disorders of the cardiovascular system in newborns. J Grodno State Med Univ. 2015;3:5-11. (In Russ.).